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Concentration-Dependent Inhibition of
Development of GGT Positive Foci in
Rat Liver by the Environmental
Contaminant Di(2-ethylhexyl) Phthalate
by A. B. DeAngelo,* A. E. Queral* and C. T. Garrett*t
The ability ofdi(2-ethylhexyl) phthalate (DEHP), a widely used plasticizer and environmental contam-
inant, to suppress development of putative preneoplastic lesions in rat liver was evaluated. y-Glutamyl
transpeptidase-positive (GGT+) foci were initiated in the livers ofSprague-Dawley male rats with a single
dose of diethylnitrosamine (DEN) following partial hepatectomy. Promotion of foci was commenced by
feeding a choline-deficient diet (CD). A group of control rats was fed a choline-supplemented diet (CS).
The ability ofDEHP to suppress the emergence ofGGT+ foci was evaluated by feeding additional groups
of rats the CD diet containing either 0.1%, 0.5%, 1.0% or 2.0% DEHP. The CD diet promoted the number
of GGT+ foci above levels in control livers. Inclusion of the plasticizer to the levels of 0.5%, 1.0% and
2.0% in the CD diet effectively inhibited the appearance ofthe foci. However, DEHP was unable to inhibit
the promoting effect of the CD diet at a concentration of 0.1%. DEHP's ability to block development of
GGT+ foci correlated with its ability to increase liver weight and to induce carnitine acetyltransferase
(EC 2.3.1.7), a marker of peroxisome proliferation.
Introduction
The diesters of o-phthalic acid are used to impart
flexibility to plastics and may comprise up to 60% by
weight of the finished product (1). DEHP, the most
widelyusedplasticizerforpolyvinylchloride (PVC), had
an estimated production volume of 280 million pounds
in the United States for 1983 (2). This compound is not
covalently bound to the PVC and can migrate out ofthe
finishedproductwithtimeand use. Thelargeproduction
volume coupled with the ability ofthe DEHP to migrate
out of the plastic yield a large potential for human ex-
posure. Although DEHP is relatively nontoxic, some
concern about its safety has arisen because a recent
study from the National Toxicology Program found that
it increased the incidence of hepatocellular carcinoma
and neoplastic nodules in rodents (3). Moreover, DEHP
shares many biochemical properties with a class of com-
pounds called peroxisome proliferators, two of which,
nafenopin and Wy-14643, have been shown to promote
the outgrowth of neoplastic foci in rat liver (4,5).
We recently examined the ability of DEHP to pro-
mote the outgrowth of GGT + foci in rats previously
administered a subcarcinogenic dose of diethylnitrosa-
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mine (6). The development of -y-glutamyl transpepti-
dase-positive (GGT+) focihasbeenclosely linked tothe
subsequent development ofboth neoplastic nodules and
hepatomas (7-9). Indeed, these foci are regarded by
many as the precursorlesionforboth neoplasticnodules
and hepatomas (8). DEHP did not enhance the pro-
motion of GGT+ lesions after either a 5 or 10 week
feeding of the compound at a 2% level. Somewhat un-
expectedly, DEHP suppressed the development of
GGT+ foci by the well established promotingregimen,
the choline- deficient diet (6). In a subsequent study we
have also shown that DEHP at a 2% level blocked the
development ofGGT+ foci followinginitiation with DEN
and promotion with phenobarbital (10). In the present
study we have demonstrated that DEHP effectively
suppressed development of GGT+ foci in the rat liver
at levels as low as 0.5% and that this possible anti-
promoting activity correlated with its ability to induce
the enzyme marker of peroxisome proliferation, carni-
tine acetyltransferase.
Materials and Methods
MaleSprague-Dawleyratsweighing 150to200gwere
housed individually in metal cages in a room with con-
stant temperature and humidity and on a 12-hr light-
dark cycle. The animals were fed a basal diet (Purina,DEANGELO, QUERAL AND GARRETT
Table 1. Number and size offoci and percent liver ofGGT-positive hepatocytes.
Dietary No. of Area,b % Liver
Groupa treatment rats Foci/cm2 112 as focic
1 CS 3 4.2 ± 0.6" 12.5 + 1.9 0.050 ± 0.005
(2,4,6)' (2) (2,4)
2 CS+2%DEHP 3 0.8 ± 0.2 4.1 ± 0.6 0.003 ± 0.001
3 CD 3 12.9 ± 2.8 18.0 ± 3.2 0.24 ± 0.081
(1,2,4,5,6) (2) (2,4,5,6)
4 CD+2%DEHP 3 0.7 ± 0.2 6.2 ± 2.9 0.005 ± 0.004
5 CD+1%DEHP 5 1.6 ± 0.7 14.8 ± 8.8 0.025 ± 0.013
6 CD+0.5%DEHP 5 1.3 ± 0.7 18.7 ± 9.9 0.031 ± 0.017
7 CD+0.1%DEHP 5 6.6 ± 2.9 16.0 ± 3.2 0.119 ± 0.052
(2)
a All rats received 30 mg/kg DEN by IP injection at 18 hr after partial hepatectomy. Dietary treatment began 10 days after injection of
DEN.
Calculated from the average ofthe measured major and minor diameters assuming the shape ofthe focus to be an ellipse.
Theproduct of(foci/cm2) x (avg. area) x 10-6, where 10 -6 iSthe reciprocal ofthe numberofsquare microns persquare centimetertimes
100.
d Mean ± SE.
e p < 0.05 by Student t-test for two-tailed differences when compared with groups in parentheses ( ).
Ralston Purina Co., St. Louis, MO) and water ad li-
bitum for at least 1 week before the start of experi-
ments. Purified CS and CD diets were prepared
according to the protocol of Shinozuka et al. (11).
For CD diets containing DEHP (Aldrich Chemical
Co., Milwaukee, WI) the compound was added to levels
of0.1%, 0.5%, 1.0%, and2.0% attheexpenseofsucrose.
DEHP was added to a CS diet at a level of 2.0% to
serve as a negative control. At 18 hr following subtotal
hepatectomy, rats were administered a single intraper-
itonealinjectionofDEN (AldrichChemicalCo.) insaline
at a dose of30 mg/kg. Ten days later groups ofanimals
(three to five rats/group) were placed on the experi-
mental or control diets as indicated in Table 1. Animal
weights and food consumption were monitored on two
consecutive days at weekly intervals. DEHP intake for
each group was calculated and averaged over the feed-
ing period. Rats were sacrificed by carbon dioxide as-
phyxiation at 10 weeks following the commencement of
the diets. Body weights and liver wet weights were
determined. The livers were perfused with 50 mL ice-
cold saline through the hepatic portal vein. Blocks of
liver, which were quickly frozen on dry ice, had 8 ,um
cryostat sections cut and stained according to the pro-
cedure ofRutenburg et al. (12). GGT+ foci were counted
and the major and minor diameter measured by an ocu-
lar micrometer. The area of each focus was estimated
assuming it to be elliptical in shape (foci are rarely true
circles). The area of the tissue section was measured
using an Apple II + computer with graphics tablet ac-
cessory. The size, numberoffocipersquare centimeter,
and the percent of tissue represented by the foci were
calculated. Statistical comparisons were by Fisher F
test and Student t test (13).
For use in the carnitine acetyltransferase (CAT) as-
say, the liver enzyme was solubilized according to the
procedure of Moody and Reddy (14). All steps were
carried out at 4°C. Briefly, a 5% homogenate was pre-
pared in a buffer containing 0.25 M sucrose, 0.116 M
TrisHCI, pH8.0, and0.0025 M EDTA. Thehomogenate
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FIGURE 1. Dietary DEHP intake. DEHP intake (mg/100 g body
weight) was calculated by measuring the consumption ofCD diets
containing 2.0%, 1.0%, 0.5%, and 0.1% of the plasticizer over a
24-hr period at weekly intervals.
was sonified for 2 min and allowed to stand overnight.
The homogenate was then centrifuged at 76,300g for 1
hr. The resulting supernatant fraction was assayed for
CAT activity by the method of Fritz and Schultz (15).
The release of acetyl coenzyme A-SH in the presence
of5,5'-dithiobis (2-nitrobenzoate) was followed spectro-
photometrically at 412 nm at 20°C, either in the pres-
ence or absence of carnitine.
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Results
Promotion offoci was commenced by feeding the CD
diet which effectively increased the number of GGT +
foci above levels in control rats fed only the CS diet
(12.93 ± 2.76 vs. 4.16 ± 0.60 foci/cm, Table 1). To
evaluate the antipromoting activity of DEHP, groups
ofratsreceivedthe CD dietcontaining 0.1%, 0.5%, 1.0%
and 2.0% DEHP. Figure 1 shows the amount ofDEHP
ingested by each group based on recorded food con-
sumptions. The amount of the plasticizer ingested in-
creased linearly with the dietary concentration from 6
mg/100 gbody weight (BW)/day foranimals onthe 0.1%
diet to 119 mg/100 g BW/day for the 2.0% treated an-
imals. This linearity reflected a constant food uptake
between the groups ofanimals fed the CD diet contain-
ing the varying amounts of the plasticizer.
The number offoci developingin the livers ofthe rats
on the various regimens is shown in Table 1. As can be
seen, the CD + 2.0% DEHP regimen decreased the
number ofGGT + foci from 12.93 ± 2.76/cm2 to 0.83 +
0.17 foci/cm2 as would be expected from our earlier study
(6). In addition, however, was the finding that plasti-
cizer concentrations of 1.0% and 0.5% were equally ef-
fective in suppressing the development offoci (Table 1).
The CD + 0.1% DEHPdietdiddecreasethe meanvalue
ofthe numberoffoci, but notto a statistically significant
degree. In addition to decreasing the number of foci
below that observed in rats on the CD diet alone, the
CD diets containing 0.5%, 1.0% and 2.0% DEHP re-
duced the number offoci below that seen forthe control
rats on the CS diet (Table 1). We had observed a similar
finding in which rats on the CS diet which had shown
significantly more foci than those fed the CS + 2.0%
DEHP diet (6). Likewise, in the present study the CS
+ 2.0% DEHP diet reduced the number of foci below
that arising from endogenous promoting factors (41.6
+ 0.60 vs. 0.83 ± 0.1).
An additional important observation was that rats fed
CD diets containing 1.0% and 0.5% DEHP had mean
body weight gains exceedingthat ofthe CD group (Fig.
2). In our previous studies, rats receiving the 2.0%
DEHP diet had sometimes demonstrated a lower mean
body weight gain than rats on the CD diet alone al-
though the magnitude of the difference was not statis-
tically significant. Nevertheless, since it had been
reported that decreased bodyweights can be associated
with diminished incidence of tumors (16), the lower
weight gain in the DEHP-treated animals raised the
remote possibility that the lower number offoci in DEHP
treated rats might represent some type of nonspecific
"starvation" effect. However, the findingthat 0.5% and
1.0% concentrations of DEHP both inhibited foci for-
mation and did not decrease total body weight gain has
eliminated that possibility.
In order to independently demonstrate that DEHP
was, in fact, exerting its usual biochemical effect in the
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FIGURE 2. Changes in total body weight with time. The net body
weight changes compared with weights measured at the beginning
of the diets are shown.
Table 2. Carnitine acetyltransferase activity and liver weight changes.
Dietary No. of CAT Liverweight,
Groupa treatment rats activity' g/100 g body weightc
1 CS 3 0.00 ± 0.00" 3.56 ± 0.24
2 CS+2%DEHP 3 4.26 ± 0.86 6.11 ± 0.35
(1,3,4,5,6,7)" (1,3,6,7)
3 CD 3 0.05 ± 0.03 3.56 ± 0.29
4 CD+2%DEHP 3 1.93 ± 0.19 5.61 ± 0.31
(1,3,7) (1,3,6,7)
5 CD+1%DEHP 5 1.55 ± 0.33 4.95 ± 0.30
(1,3,7) (1,3,7)
6 CD+0.5%DEHP 5 1.45 ± 0.11 4.59 ± 0.08
(1,3,7) (1,3,7)
7 CD+0.1%DEHP 5 0.14 ± 0.07 4.12 ± 0.06
(1)
a All rats received 30 mg/Kg DEN by IPinjection at 18 hr after partialhepatectomy. Dietary treatment began 10 days after injection of
DEN.
bCarnitine acetyltransferase activity is expressed as ,umole coenzymeASH released/mg protein/min.
c Mean ± SE.
dp < 0.05 by Student t-test for two-tailed differences when compared with groups in parentheses ( ).
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livers of animals fed either the CS or CD diets, we
measured the induction of carnitine acetyltransferase
(CAT). The activity ofthis enzyme parallels peroxisome
proliferation (14), a process which is thought to be in
part responsible for the alleged tumor inducing activity
of DEHP (17,18). Little or no CAT activity was meas-
ured in the livers of rats fed the CS or CD diet alone
(Table 2). Moreover, the CD + 0.1% DEHP diet which
failed to inhibit the outgrowth ofpreneoplastic foci (Ta-
ble 1) also failed to induce CAT activity above that of
the CD diet. The CD diets containing 0.5%, 1.0%, and
2.0% DEHP and the CS + 2.0% DEHP diet all in-
creased CAT activity above control levels. This effect
of DEHP on liver CAT activity was also paralleled by
its well known effect on liver weight. DEHP increased
liver weight (g/100 g body weight) when present in the
diet at 2.0%, 1.0%, and 0.5% (Table 2) but was ineffec-
tive at 0.1%. Thus, the ability of DEHP to inhibit the
outgrowth of GGT+ foci was directly correlated with
induction of CAT activity and increased liver weight,
two well documented effects of the plasticizer.
Discussion
DEHP, while not genotoxic (18,19), was shown in one
recent study to increase the incidence of liver tumors
when fed at a dose of 1.2% in the diet ofFisher 344 rats
(3) and in another study to increase the number ofpre-
neoplastic basophilic foci in the livers of mice given a
subcarcinogenic dose of DEN (20). However, in earlier
studies ofthis compound, it did not show a tumorigenic
effect when incorporated into the diets of rats (21,22).
In our studies (6,10), DEHP has consistently sup-
pressed the development of putative preneoplastic
GGT+ foci when administered in the diets ofrats given
a subearcinogenic dose of DEN. The results in this re-
port have shown that this effect was dose related and
that it correlated directly with otherknownbiochemical
effects of DEHP. DEHP fed at levels of 0.5%, 1.0%,
and 2.0% suppressed the emergence of preneoplastic
foci while at a level of 0.1% it was not effective. Cor-
respondingly, DEHP caused asignificant increase inthe
activity of CAT, a marker of peroxisome proliferation
(14) and liver weights at doses of the compound which
inhibited the appearance of GGT+ foci but not at the
level of 0.1% which was ineffective in suppressing pro-
motion. This finding ofa dose relationship adds further
important evidence to our earlier studies suggesting
that this compound may have antitumor promoting ac-
tivity in the rat liver carcinogenesis model.
We have been interested in possible mechanisms which
might explain DEHP's inhibition of GGT+ foci devel-
opment. Foci presumably arise from carcinogen- initi-
ated hepatocytes which have acquired the ability for
"semi-autonomous" growth (7,8). Suppression of this
growth may be due to DEHP's effects on membrane-
bound enzymes. DEHP is lipophilic and can suppress
the activity ofHMG CoAreductase (3-hydroxy-3- meth-
ylglutaryl CoA reductase, EC 1.1.1.34) which is the
enzyme responsible for the regulation of de novo cho-
lesterogenesis (23). This action could provide one mech-
anismbywhich DEHP might suppress cellgrowth since
intermediates from the synthesis of cholesterol appear
to be required forcell division (24,25). We are currently
studying another group of membrane-bound enzymes
which appear to be affected by DEHP. These are the
liver cell plasma membrane protein kinases (26). Our
results indicate that chronic feeding of DEHP results
in inhibition ofthe ability ofepidermal growth factor to
stimulate the autophosphorylation ofits 175,000 plasma
membrane receptor protein (26).
The reason forthe apparent discrepancy between our
results demonstrating possible antipromoting activity
by DEHP and the results of others demonstrating tu-
morigenic or promoting activity for this compound and
several other peroxisome proliferators is unclear at this
juncture. Recently, the peroxisome proliferators, BR-
931 and nafenopin, were shown to suppress the devel-
opmentofGGT+ fociinratsinitiatedwith DEN (27,28).
While differences in methodological detail were present
betweenthe studies showingpromotionandthose show-
ing possible antipromotion, no obvious difference was
noted which could explain the apparent discrepancy in
results. One possible explanation could be that DEHP
suppresses the development of those foci which would
regress anyway, since most foci presumably do not de-
velop into neoplastic nodules or hepatomas (29). Alter-
natively, if the development of neoplastic nodules and
hepatomas proceeds through pathways other than the
formation ofGGT+ foci as has been suggested by some
(30), then DEHP's ability to suppress development of
GGT + foci would not necessarily indicate a true anti-
promoting activity. We are currently extending our
studies with DEHP to further clarify this question.
This work was supported by NCI 1-RO1-CA-31324 awarded by the
National Cancer Institute, Department of Health and Human Serv-
ices. We gratefully acknowledge the technical assistance of Ms. Lia
Anna Manolukas and the secretarial assistance of Ms. Susan Garrett
and Mrs. Viann Powers.
REFERENCES
1. Autian, J. Toxicity and health threats of phthalate esters: a re-
view ofthe literature. Environ. Health Perspect. 4: 3-26 (1973).
2. United States International Trade Commission. Preliminary Re-
port on U.S. Production ofSelected Organic Chemicals (Including
Synthetic Plastics and Resins) March, April, and Cumulative To-
tals, 1983. U.S. Trade Commission, Washington, DC Series C/P-
83-4 (1983).
3. National Toxicological Program. Carcinogenesis bioassay ofdi(2-
ethylhexyl) phthalate. DHSS Publication No. (NIH) 81-1773.
Carcinogen Testing Program, National Toxicology Program, Re-
search Triangle Park, NC (1982).
4. Schulte-Hermann, R., Ohde, G., Schuppler, J., and Timmer-
mann- Trosiener, I. Enhanced proliferation of putative preneo-
plastic cells in rat liverfollowing treatment with tumor promoters
phenobarbital, hexachlorocyclohexane, steriod compounds and
nafenopin. Cancer Res. 41: 2556-2562 (1981).
5. Reddy, J. K., and Rao, M. S. Enhancement by Wy-14643, a
hepatic peroxisome proliferator of diethylnitrosamine-initiatedINHIBITION OF GGT-POSITIVE FOCI BY DEHP 385
hepatic tumorigenesis in the rat. Brit. J. Cancer 38: 537-543
(1978).
6. DeAngelo, A. B., and Garrett, C. T. Inhibition of development
of preneoplastic lesions in the livers of rats fed a weakly carcin-
ogenic environmental contaminant. Cancer Letters 20: 199-205
(1983).
7. Solt, D. B., Medline, A., and Farber, E. Rapid emergence of
carcinogen-induced hyperplastic lesions in a new model for the
sequential analysisoflivercarcinogenesis. Am. J. Pathol. 88: 595-
618 (1977).
8. Pitot, H. C., and Sirica, A. E. The stages of initiation and pro-
motion in hepatocarcinogenesis. Biochem. Biophys. Acta 605: 191-
215 (1980).
9. Pitot, H. C., Barsness, L., and Goldsworthy, T. Biochemicalchar-
acterization of stages of heptocarcinogenesis after a single dose
ofdiethyl-nitrosamine. Nature 271: 456-458 (1978).
10. DeAngelo, A. B., Garrett, C. T., and Queral, A. E. Inhibition of
phenobarbitol and dietary choline deficiency-promoted prenco-
plastic lesions in rat liver by the environmental contaminant di(2-
ethylhexyl)phthalate. Cancer Letters 23: 323-330 (1984).
11. Chinozuka, H., Lombardi, B., Sell, S., and lammarion, R. M.
Early histological and functional alterations ofethionine liver car-
cinogenesis in rats fed a choline deficient diet. Cancer Res. 38:
1092-1098 (1978).
12. Rutenburg, A. M., Hwakyu, K., Fischbein, J. W., Hanker, J.
S., Wasserkrug, H. L., and Seligman, A. M. Histochemical and
ultrastructural demonstration of y-glutamyltranspeptidase activ-
ity. J. Histochem. Cytochem. 17: 517-526 (1969).
13. Snedecor, G. W., and Cochran, W. G. Statistical Methods. Iowa
State University Press, Ames, 10, 1980, pp. 215-236, 365-385.
14. Moody, D. E., and Reddy, J. K. Increase in hepatic carnitine
acetyltransferase activity associated with peroxisomal (micro-
body) proliferation induced bythe hypolipidemic drugs clofibrate,
nafenopin, and methyl clofenapate. Res. Commun. Chem. Path.
Pharm. 9: 501-510 (1974).
15. Fritz, I. B., and Schultz, S. K. Carnitine acetyltransferase. II.
Inhibition bycarnitine analogues and sulfhydryl reagents. J. Biol.
Chem. 240: 2188-2192 (1965).
16. Tannenbaum, A., and Silverstone, H. Nutrition in relation to
cancer. Adv. Cancer Res. 1: 451-501 (1953).
17. Moody, D. E., and ReddyJ. K. Hepatic peroxisome (microbody)
proliferation in rats fed plasticizers and related compounds. Tox-
icol. Appl. Pharmacol. 45: 497-504 (1978).
18. Warren, J. R., Lalwani, N. D., and Reddy,J. K. Phthalate esters
as peroxisome proliferator carcinogens. Environ. Health Per-
spect. 45: 35-40 (1982).
19. Zeiger, E., Haworth, S., Peck, W., andMortelmans, K. Phthalate
ester testing in the national toxicology program's environmental
mutagenesis test development program. Environ. Health Per-
spect. 45: 99-101 (1982).
20. Ward. J., Rice, J. M., Creasia, D., Lynch, P., and Riggs, C.
Dissimilar patterns of promotion by di(2-ethylhehyl) phthalate
and phenobarbital of hepatocellular neoplasia initiated by dieth-
ylnitrosamine inB6C3F1 mice. Carcinogenesis4: 1021- 1029(1983).
21. Carpenter, C., Weil, C., and Smyth, H. Chronic oral toxicity of
di(2-ethylhexyl) phthalate for rats, guinea pigs, dogs. Arch. Ind.
Hyg. Occup. Med. 8: 219-226 (1953).
22. Harris, R., Hodge, C., Maynard, E., and Blanchet, H. Chronic
oral toxicity of 2-ethylhexyl phthalate in rats and dogs. Arch.
Ind. Health 13: 259-264 (1956).
23. Bell, F. P. Effects of phthalate esters on lipid metabolism in
various tissues, cells and organelles inmammals. Environ. Health
Perspect. 45: 41-50 (1982).
24. Chen, H. Roleofcholesterol metabolismincellgrowth. Fed. Proc.
43: 126-130 (1984).
25. Quesney-Huneeus, V., Wiley, M. H., and Siperstein, M. D. Es-
sential role for mevalonate synthesis in DNA replication. Proc.
Natl. Acad. Sci. (U.S.) 76: 5056-5060 (1979).
26. DeAngelo, A. B., Garrett, C. T., and Queral, A. E. Phospho-
rylation of specific plasma membrane proteins during promotion
ofpreneoplastic hepatic lesions and inhibition by di(2-ethylhexyl)
phthalate (DEHP). Proc. Am. Assoc. Cancer Res. 25: 141 (1984).
27. Shinozuka, H., Abanobi, S. E., and Lombardi, B. Modulation of
tumor promotion in liver carcinogenesis. Environ. Health Per-
spect. 50: 163-168 (1983).
28. Staubli, W., Bentley, P., Bieri, F., Frohlich, E., and Waechter,
F. Inhibitory effect of nafenopin upon the development of dieth-
ylnitrosamine-induced altered foci within the rat liver. Carcino-
genesis 5: 1-46 (1984).
29. Moore, M., Hacker, H., and Bannasch, P. Phenotypic instability
in focal and nodular lesions induced in a short term system in the
rat liver. Carcinogenesis 4: 595-603 (1983).
30. Sell, S., and Salman, J. Light- and electron-microscopic autora-
diographic analysis of proliferating cells during the early stages
of chemical hepatocarcinogenesis in the rat induced by feeding
N-2-fluorenylacetamide in a choline-deficient diet. Am. J. Pathol.
114: 287-300 (1984).